Two-year outcome of elderly patients with anxious depression

doi:10.1016/S0165-1781(96)02964-2

Psychiatry Research

Volume 66, Issue 1, 15 January 1997, Pages 23-31

https://doi.org/10.1016/S0165-1781(96)02964-2 Get rights and content

Abstract

The purpose of this study was to determine whether there was a difference in the long-term outcome between elderly patients with anxious depression and those with non-anxious depression. Eighty-three patients with non-bipolar, non-psychotic major depression who had responded to treatment of the index episode were maintained on full-dose antidepressant medication and followed on a monthly basis over a period of 2 years. Anxiety status at index assessment was not related to outcome as defined by rates of relapse and recurrence or time to these events. However, the few patients who remained anxious at the point of remission of the index episode had a significantly shorter time to relapse/recurrence. These findings suggest that, once they achieve remission and are given adequate prophylactic treatment, most older patients with anxious depression have a similar long-term outcome to patients without anxiety.

References (28)

G.S. Alexopoulos et al.
Chronicity and relapse in geriatric depression
Biol Psychiatry
(1989)
A.J. Flint et al.
The effect of sequential antidepressant treatment on geriatric depression
J Affect Disord
(1996)
M.F. Folstein et al.
‘Mini-Mental State’. A practical method of grading the cognitive state of patients for the clinician
J Psychiatr Res
(1975)
P. Tyrer et al.
The Nottingham study of neurotic disorder: comparison of drug and psychological treatments
Lancet
(1988)
C. Van Valkenburg et al.
Anxious depressions: clinical, family history, and naturalistic outcome-comparisons with panic and major depressive disorders
J Affect Disord
(1984)
P.W. Burvill et al.
Quantification of physical illness in psychiatric research in the elderly
Int J Geriatr Psychiatry
(1990)
P.J. Clayton et al.
Follow-up and family study of anxious depression
Am J Psychiatry
(1991)
J.R.M. Copeland et al.
The prevalence and outcome of anxious depression in elderly people aged 65 and over living in the community
W. Coryell et al.
Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data
Am J Psychiatry
(1988)
W. Coryell et al.
Anxiety syndromes as epiphenomena of primary major depression: outcome and familial psychopathology
Am J Psychiatry
(1992)

S.C. Dilsaver

Withdrawal phenomena associated with antidepressant and antipsychotic agents

Drug Saf

(1994)

C. Faravelli et al.

Depressive relapses and incomplete recovery from index episode

Am J Psychiatry

(1986)

A.J. Flint

The optimum duration of antidepressant treatment in the elderly

Int J Geriatr Psychiatry

(1992)

A.J. Flint

Epidemiology and comorbidity of anxiety disorders in the elderly

Am J Psychiatry

(1994)

Cited by (70)

Therapeutic potential of mangiferin in the treatment of various neuropsychiatric and neurodegenerative disorders
2021, Neurochemistry International
Xanthones are important chemical class of bioactive products that confers therapeutic benefits. Of several xanthones, mangiferin is known to be distributed widely across several fruits, vegetables and medicinal plants. Mangiferin has been shown to exert neuroprotective effects in both in-vitro and in-vivo models. Mangiferin attenuates cerebral infarction, cerebral edema, lipid peroxidation (MDA), neuronal damage, etc. Mangiferin further potentiate levels of endogenous antioxidants to confer protection against the oxidative stress inside the neurons. Mangiferin is involved in the regulation of various signaling pathways that influences the production and levels of proinflammatory cytokines in brain. Mangiferin cosunteracted the neurotoxic effect of amyloid-beta, MPTP, rotenone, 6-OHDA etc and confer protection to neurons. These evidence suggested that the mangiferin may be a potential therapeutic strategy for the treatment of various neurological disorders. The present review demonstrated the pharmacodynamics-pharmacokinetics of mangiferin and neurotherapeutic potential in several neurological disorders with underlying mechanisms.
Anxiety and somatic symptoms among elderly patients with depression
2019, Asian Journal of Psychiatry
This study aimed to evaluate the symptom profile, including anxiety and somatic symptoms among elderly patients with depression using the Geriatric depression scale (GDS-30), Beck Depression Inventory (BDI), Generalized anxiety Disorder -7 Scale (GAD-7) and Patient Health Questionnaire-15 (PHQ-15) scale. Additional aim was to carry out the factor analysis of symptoms reported on various scales.
83 elderly patients (age ≥60 years) with depression were evaluated on GDS-30, BDI, GAD-7 and PHQ-15.
60 subjects (72.28%) had GAD-7 score of ≥10, which is indicative of significant anxiety. On PHQ-15, 98.8% of patients had moderate to severe somatization. There was no correlation between severity of depressive symptoms (as assessed by GDS-30 and BDI) with anxiety and depressive symptoms except for significant correlation between BDI total score and GAD-7 total score (Pearson correlation coefficient-0.319;p = 0.003).Factor analysis of GDS-30 yielded a five factor solution and when the items of other 3 scales were added, the number of factors/symptoms clusters increased to 7.
The present study suggests that there is a higher prevalence of anxiety and somatic symptoms in elderly patients with depression and GDS-30 is unable to capture all the symptoms of depression among elderly in the Indian context. Hence, complete assessment of depression in elderly should include assessment of anxiety and somatic symptoms by using other scales like GAD-7,BDI-II and PHQ-15. There is a need to develop a new scale which will be helpful in capturing the entire symptom profile of depression among elderly.
An investigation of vulnerability factors for depression
2017, Personality and Individual Differences
Citation Excerpt :
Anxiety can prevent individuals from coping effectively with threatening situations, causing a decrease in performance and functioning in everyday life. Many studies have found anxiety to be highly prevalent among patients with Major Depressive Disorder (MDD; Flint & Rifat, 1997; Wehry et al., 2015). Feske, Frank, Kupfer, Shear, and Weaver (1998) compared patient anxiety levels in a sample of individuals diagnosed with unipolar depression.
Previous studies have found that difficulty accepting the past mediates the predictive relationship between depression and socially prescribed perfectionism. This relationship inspired the present study to examine relations between a variety of personality traits - shame, anxiety, perfectionism and difficulty accepting the past - which pose as vulnerability factors for depressive symptoms. A single multi-faceted questionnaire was administered to 163 university students and 119 general public participants. Supporting predictions, socially prescribed perfectionism yielded a weaker relationship with depression than did anxiety, shame, and accepting the past.
Suboptimal response to antidepressant therapy: Definition and clinical implications
2011, Quaderni Italiani di Psichiatria
La scarsa o inadeguata risposta ai trattamenti antidepressivi costituisce un problema di notevole rilevanza per le sue conseguenze cliniche e psicosociali.
Basandosi su un’estensiva analisi della letteratura, si fornisce una possibile definizione operativa di risposta subottimale ai trattamenti, si riportano i dati sulla sua frequenza e se ne descrivono le implicazioni sul piano clinico e psicosociale.
La frequenza di risposte subottimali dopo un singolo trattamento antidepressivo supera il 70% dei casi, sebbene nel tempo e col ripetersi dei tentativi terapeutici essa possa ridursi a un terzo circa dei casi. La presenza di una risposta subottimale, in termini di risposte parziali o di sintomi residui sottosoglia in pazienti remitter, è associata a tassi di recidiva/ricaduta maggiori e a ricadute/recidive più precoci, nonché a maggiori rischi di cronicità, suicidalità, ridotto funzionamento sociale e aumentati costi sanitari.
La frequenza e le conseguenze della risposta subottimale rappresentano una sfida per il clinico e implicano la messa in atto nel tempo di diverse strategie complesse (augmentation, add-on, switching) al fine di superare i limiti del trattamento.
Insufficient responses to antidepressant drugs can be an important problem, with negative clinical and psychosocial consequences.
On the basis of an extensive analysis of the existing literature, the authors provide a possible operational definition of suboptimal treatment response and review the available data on the frequency of this phenomenon and its implications.
A suboptimal response to antidepressant therapy is defined as a partial response or one that includes residual sub-threshold symptoms. These responses are associated with an increased risk for recurrence/relapses, shorter times to recurrence/relapse, higher risks of disease chronicity and suicidal tendencies, reduced functioning, and increases in the costs of care. Suboptimal responses are observed in approximately 70% of all patients after the first cycle of treatment, but with repeated attempts at treatment, this rate drops to approximately one third of cases.
Given their frequency and negative consequences, suboptimal responses to antidepressant therapy can be a challenge for clinicians, and complex strategies (e.g., augmentation, add-on, or switching) are often needed to overcome the limitations of the treatment.
Meeting highlights on mood disorders: The 3<sup>rd</sup> annual chair summit
2011, Health Outcomes Research in Medicine
Citation Excerpt :
Antidepressant treatment has been commonly used to treat anxious depression.44 While the various antidepressants are generally equally efficacious in anxious depression,35 there is some evidence that the response to these agents in anxious depression may be lower than in MDD.45,46 It has also been shown that when anxiety persists, despite response, there is a greater likelihood of relapse of depressive symptoms.46
Mood disorders are among the most common neuropsychiatric disorders. Major depressive disorder and bipolar disorder affect 14.8 million (6.7%) and 5.7 million (2.6%) adults in the United States aged 18 years and over in a given year, respectively; and these may be conservative estimates. In addition, these disorders are associated with significant disability and morbidity for the patient, and enormous societal costs. Regrettably, mortality is too common for patients affected; more than 90% of people who commit suicide have a diagnosable mental disorder, most commonly a depressive disorder.
The 3^rd Annual Chair Summit, The Master Class for Neuroscience Professional Development, held in Chicago, Illinois (August 2010), a comprehensive continuing medical education (CME) conference on neuroscience targeted to psychiatry and neurology clinicians and featuring relevant department chairs as faculty, included numerous educational sessions on unipolar and bipolar mood disorders. Notable topics in depression were management of subtypes (psychotic and anxious), onset in late life, available evidence regarding use of complementary and alternative medicine, and the impact of depression treatment on cardiovascular disease. Bipolar disorder sessions focused on patients with childhood onset of illness and those who require systematic therapy trials in order to arrive at the optimal, individualized treatment plan. Additionally, a forward-looking session was held on innovations, both diagnostic and therapeutic, on the horizon for improving care of bipolar disorder. This 2nd article of 5 in a CME-certified companion series presents highlights of these sessions with summary points connecting research to clinical practice for each topic.
Economic impact of nonpersistence with antidepressant treatment in the adult population of Quebec: A comparative cost-effectiveness approach
2011, Value in Health
Citation Excerpt :
Depression is one of the most frequent psychiatric disorders in the general population [1–4], with more than half of depressed subjects experiencing substantial functional impairment [3]. Lack of treatment is associated with increased mortality, morbidity, use of health-care services, institutionalization, and health-care costs [5–8]. Depression is increasingly considered as a relapsing-remitting illness and is a chronic disease.
Although for the great majority of indications, practice guidelines recommend that antidepressants (ADs) be used for at least 6 months, premature discontinuation is very frequent in a “real-life” setting. Previous studies have assessed the economic impact of such nonpersistence, but differences across antidepressant products remain inadequately explored.
To compare treatment persistence and incremental cost/persistence ratios (ICPRs) across individual new ADs (selective serotonin reuptake inhibitors and atypical ADs) as well as the associated direct health-care costs in the adult population covered by the public drug program of Quebec.
A retrospective cohort study was conducted in 13,936 adults aged 18 to 64 years who started an AD treatment in 2003. Persistence was defined as treatment duration of at least 6 months regardless of whether a product switch had occurred. Economic impact was assessed over the first year of treatment through drug, medical services, hospitalization, and total health-care costs. Comparisons across products were conducted using the ICPR.
Adjusting for confounders, treatment nonpersistence ranged from 60.4% (paroxetine) to 65.1% (citalopram). The product associated with the highest total health-care costs was citalopram (CDN$2653) and the lowest was venlafaxine (CDN$2168). Fluvoxamine had the lowest mean AD costs (CDN$215) and venlafaxine (CDN$309) the highest.
Total health-care costs were similar across products except for citalopram, which was more costly. Comparisons based on the ICPR revealed that paroxetine, fluoxetine, and venlafaxine were more favorable than the other AD alternatives.

View all citing articles on Scopus

View full text

ArticleTwo-year outcome of elderly patients with anxious depression

Abstract

Biol Psychiatry

J Affect Disord

J Psychiatr Res

Lancet

J Affect Disord

Quantification of physical illness in psychiatric research in the elderly

Int J Geriatr Psychiatry

Follow-up and family study of anxious depression

Am J Psychiatry

The prevalence and outcome of anxious depression in elderly people aged 65 and over living in the community

Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data

Am J Psychiatry

Anxiety syndromes as epiphenomena of primary major depression: outcome and familial psychopathology

Am J Psychiatry

Withdrawal phenomena associated with antidepressant and antipsychotic agents

Drug Saf

Depressive relapses and incomplete recovery from index episode

Am J Psychiatry

The optimum duration of antidepressant treatment in the elderly

Int J Geriatr Psychiatry

Epidemiology and comorbidity of anxiety disorders in the elderly

Am J Psychiatry

Article
Two-year outcome of elderly patients with anxious depression